SCHEMBL30717460

SCHEMBL30717460

O=C(CC1CCCC1)N1CCc2nc(N3CCN4CCC[C@@H]4C3)sc2C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 7/20 0.43
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
NPC1 O15118 2/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
OGA O60502 1/20 0.34
F10 P00742 1/20 0.33
UCHL1 P09936 2/20 0.33
MAPK14 Q16539 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
PARK7 Q99497 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30717447 1.00 GRM5 (0.43) GRM5ADORA2AADORA1NPC1RAB9A
SCHEMBL30717448 0.81 ADORA2A (0.45) GRM5ADORA2AADORA1NPC1RAB9A
SCHEMBL31748855 0.81 ADORA2A (0.47) GRM5ADORA2AADORA1NPC1RAB9A
SCHEMBL30717361 0.80 ADORA2A (0.45) GRM5ADORA2AADORA1NPC1RAB9A
SCHEMBL30717397 0.79 ADORA2A (0.42) GRM5ADORA2AADORA1NPC1RAB9A
SCHEMBL30717316 0.79 ADORA2A (0.42) GRM5ADORA2AADORA1NPC1RAB9A
SCHEMBL30717326 0.78 GRM5 (0.44) GRM5ADORA2AADORA1NPC1RAB9A
SCHEMBL30717555 0.78 GRM5 (0.44) GRM5ADORA2AADORA1NPC1RAB9A
SCHEMBL30790827 0.78 HRH3 (0.43) GRM5ADORA2AADORA1NPC1KDM4E
SCHEMBL31748905 0.77 GRM5 (0.42) GRM5ADORA2AADORA1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 US claimed
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 EP claimed
WO-2024038128-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2024-02-22 WO claimed
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 US disclosed
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 EP disclosed
WO-2024038128-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2024-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388604-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B GRM5 2029/4885ADORA2A 67/4885ADORA1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.